News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: MicuRx Pharmaceuticals Raises $25 Million for Antibiotic Clinical Trial


8/26/2013 9:02:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 24, 2013 --MicuRx Pharm of San Francisco and Shanghai raised $25 million in a Series B round to fund Phase II trials of its antibiotic for drug-resistant infections; Wanbang Pharma, a subsidiary of Fosun, signed an LOI to in-license China rights for a diabetes 2 treatment from Sirona Biochem of Canada; Suzhou-based Innovent partnered with Adimab of the US to discover and develop a new mAb for an unspecified target; Zhejiang Beta spent just $20-$30 million to develop a EGRF treatment for lung cancer, a large market in China; Eli Lilly was accused by a former manager of bribing doctors to promote sales in China; and BeiGene of Beijing announced a Scientific Advisory Board that includes an international list of experts with experience in oncology drugs. More details….

Stock Symbols: (SHA: 600196; HK: 2196) (TSX: SBM) (NYSE: LLY)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES